Biomarkers in Metastatic Colorectal Cancer
Biomarkers in Metastatic Colorectal Cancer: Clinical Utility, Examples, and Testing
Speakers: Marwan G. Fakih, M.D.
Duration: 20 minutes
Presented on: December 20, 2019
*This session is not eligible for AMA PRA Category 1 CreditsTM
Marwan G. Fakih, M.D.
Marwan G. Fakih, M.D.Dr. Marwan Fakih received his medical degree from the American University of Beirut, Lebanon, in 1992. He subsequently completed a residency in Internal Medicine at the Detroit Medical Center/ Wayne State University (1992-95) and a fellowship in Hematology and Oncology at University of Pittsburgh (1998-2001). Over the last 18 years, his career has focused on gastrointestinal malignancies and early phase 1 trials/drug development. Dr. Fakih spent 9 years at Roswell Park Cancer Institute (RPCI) where he was appointed as a tenured-track Associate Professor in Internal Medicine (University at Buffalo/ RPCI) and served as Head of the Gastrointestinal Cancer Section. He subsequently joined University of Michigan as Professor of Medicine in 2010, where he served as the Director of the Gastrointestinal Cancer program. Dr. Fakih joined City of Hope in November of 2011 where he serves as the Section Head of Gastrointestinal Cancers in the Medical Oncology and Therapeutics Research Department, Medical Director of the Briskin Center for Clinical Research, and Co-Director of the GI Cancers Program and the Phase I Program.
Dr. Fakih serves on numerous national committees, including the NCI Colorectal Cancer Task Force, SWOG Gastrointestinal Cancer core committee, NRG Colorectal Cancer core committee, and ACCRU Gastrointestinal Cancer core committee. He has conducted numerous investigator-initiated trials in patients with solid tumors and colorectal cancer, which include cytotoxic agents, HDAC inhibitors, calcitriol, selenomethionine, anti-EGFR agents, and MEK inhibitors. He is currently conducting several investigator-initiated efforts at City of Hope which include biomarker research in colorectal cancer, targeted therapy, and combination immunotherapy in early phase development in GI cancers. Dr. Fakih has published more than 150 peer-reviewed articles and serves on the editorial boards of several scientific journals.